CKD 702
Alternative Names: CKD-702Latest Information Update: 11 Feb 2026
At a glance
- Originator Chong Kun Dang
- Developer Chong Kun Dang; National Cancer Center (Korea)
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Mesenchymal stem cell therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastric cancer; Non-small cell lung cancer
Most Recent Events
- 11 Feb 2026 Discontinued - Phase-I for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (IV)
- 11 Feb 2026 Discontinued - Phase-II for Gastric cancer (Second-line therapy or greater, Combination therapy) in South Korea (IV)
- 25 Apr 2025 CKD 702 is still in phase I trials for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (IV) (NCT04667975)